DOVER, Del. & TEL AVIV, Israel - eTradeWire -- VALFIX Medical, a leading innovator in Transcatheter mitral valve repair is proud to announce the approval of its fifth consecutive grant from the Israel Innovation Authority (IIA). This latest endorsement marks a continued partnership between VALFIX Medical and the esteemed IIA, signifying a steadfast commitment to the company's vision and technological advancements.

Eli Bar, CEO of VALFIX Medical, expressed his gratitude, stating, "This grant is a testament to the IIA's trust in the VALFIX team and the transformative potential of our technology. In these turbulent times, we are confident that the grant, coupled with additional financial support from our investors, positions us to achieve our objectives. We eagerly anticipate progressing towards our first-in-human study within the next 12 months."

More on eTradeWire News

• MetaDroom Sets to Become Potential Crypto in 2025
• GBAMFS Condemns Restrictive Publisher Policies Threatening Gamer Free Expression
• Upcoming Book "Democratizing Violence: The Rise of Open-Source Warfare and the Decline of State Control" Available for Pre-Order Now
• Real Recovery Podcast: Amplifying Voices in the Recovery Movement
• SUN & STARS INT'L FILM FESTIVAL Announces Closing Night Film & Attending VIPs

VALFIX Medical has been the recipient of more than 3 million USD in grants from the Israel Innovation Authority since 2017. The approval process for these grants involves rigorous due diligence, encompassing a comprehensive review of the company's ongoing achievements, progression, execution, assets, and plans.

VALFIX has developed an innovative transcatheter system to treat Heart Failure patients suffering from significant Functional Mitral Regurgitation (FMR). VALFIX's unique and innovative technology offers a viable alternative to open heart surgery. To learn more about VALFIX Medical, visit our website at www.valfixmed.com or contact us directly at info@valfixmed.com.